21 December 2017
CLINUVEL PHARMACEUTICALS LTD today announced that the first draft assessment from England’s National Institute for Health and Care Excellence (NICE) has been published, with SCENESSE® (afamelanotide 16mg) not recommended for reimbursement for the ultra-orphan disorder erythropoietic protoporphyria (EPP), subject to NICE’s final recommendation expected in May 2018. SCENESSE® is the only approved treatment for EPP patients in Europe and is currently under review as a highly specialised technology (HST) in England.
Download PDF for more